BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman Sells 932 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 932 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $20.11, for a total transaction of $18,742.52. Following the sale, the chief financial officer now owns 188,310 shares in the company, valued at approximately $3,786,914.10. This trade represents a 0.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, April 1st, Troy Wichterman sold 25,687 shares of BioLife Solutions stock. The shares were sold at an average price of $22.66, for a total value of $582,067.42.
• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total value of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total transaction of $4,219.86.

BioLife Solutions Trading Up 4.3 %

BioLife Solutions stock opened at $21.90 on Friday. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The stock has a market capitalization of $1.03 billion, a PE ratio of -20.66 and a beta of 1.93. The firm has a 50 day simple moving average of $25.04 and a 200-day simple moving average of $25.34.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same period last year, the company posted ($0.21) EPS. As a group, equities research analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. StockNews.com upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright lifted their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Northland Securities boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Benchmark restated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $31.17.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in BioLife Solutions by 1.1% in the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock valued at $84,097,000 after acquiring an additional 36,176 shares during the last quarter. Fred Alger Management LLC grew its stake in shares of BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock worth $41,386,000 after purchasing an additional 16,274 shares during the last quarter. State Street Corp raised its holdings in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Millennium Management LLC boosted its holdings in BioLife Solutions by 49.1% during the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after buying an additional 377,111 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in BioLife Solutions by 4.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock worth $23,028,000 after buying an additional 40,416 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.